Please login to the form below

Not currently logged in
Email:
Password:

Reynolds-MacKenzie bolsters its leadership team

Nita Ares and Jennifer Garratt join, while Monica Small is promoted

Reynolds-MacKenzie has appointed two new directors and promoted a third, as part of its growth strategy.

The move sees Nita Ares and Jennifer Garratt join, while Monica Small takes on a new role, and the trio will join managing directors Alison Mackenzie and Eva Reynolds on the London-based PR agency's leadership team.

Nita Ares, Reynolds-MacKenzie 

Appointed as head of UK operations, Nita Ares joins the company with over 15 years' experience of running UK campaigns, on agency-side and in-house at the NHS.

She has held senior positions at Ketchum, South London and Maudsley NHS Foundation Trust and Biosector 2, while most recently she has worked as a freelance healthcare public relations consultant.

Jennifer Garratt, Reynolds-MacKenzie, cx 

Meanwhile, Jennifer Garratt, who has over 12 years' experience of PR and medical education, has been recruited to lead the international side of Reynolds-MacKenzie's business.

Most recently Garratt led the healthcare team at Burson-Marsteller, where she oversaw the agency's global and pan-European accounts.

Finally, Monica Small (née Shuman) has been promoted to director level, following six years with the agency. Small will provide strategic counsel to both international and UK clients.

“The new look leadership team at Reynolds-MacKenzie comprises some of the most talented and committed people in our business,” said Reynolds.

"We are confident that having this new team in place will not only help us optimise our excellent client service, which no doubt draws our clients to Reynolds-MacKenzie, but also ensure we keep growing our client base and continue to succeed long-term.”

17th August 2012

From: Marketing, Healthcare

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics